

# Ontario Public Drug Programs

---

Drug Submission Status

Report for February 2018

## Complete Streamlined Multiple-Source

### Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Natco Pharma (Canada) Inc.	Nat-Osetamivir	Tamiflu	oseltamivir phosphate	30mg	capsule	02472635
Natco Pharma (Canada) Inc.	Nat-Osetamivir	Tamiflu	oseltamivir phosphate	45mg	capsule	02472643
Taro Pharmaceuticals Inc.	Taro-Acitreten	Soriatane	acitretin	10mg	capsule	02466074